These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2573629)

  • 1. Sulfasalazine-induced impotence: a beneficial resolution with olsalazine?
    Ireland A; Jewell DP
    J Clin Gastroenterol; 1989 Dec; 11(6):711. PubMed ID: 2573629
    [No Abstract]   [Full Text] [Related]  

  • 2. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. The Ulcerative Colitis Multicenter Study Group.
    Rijk MC; van Lier HJ; van Tongeren JH
    Am J Gastroenterol; 1992 Apr; 87(4):438-42. PubMed ID: 1348159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis.
    Garau P; Orenstein SR; Neigut DA; Kocoshis SA
    J Pediatr Gastroenterol Nutr; 1994 May; 18(4):481-5. PubMed ID: 7520936
    [No Abstract]   [Full Text] [Related]  

  • 4. [Salazosulfapyridine or 5-aminosalicylic acid].
    van Hees PA
    Ned Tijdschr Geneeskd; 1987 May; 131(22):931-4. PubMed ID: 2885762
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
    Habal FM; Greenberg GR
    Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study.
    Nilsson A; Danielsson A; Löfberg R; Benno P; Bergman L; Fausa O; Florholmen J; Karvonen AL; Kildebo S; Kollberg B
    Am J Gastroenterol; 1995 Mar; 90(3):381-7. PubMed ID: 7872274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
    Baker DE; Kane S
    Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.
    Ferry GD; Kirschner BS; Grand RJ; Issenman RM; Griffiths AM; Vanderhoof JA; Fiedorek SC; Winter HS; Hassall EG; Watkins JB
    J Pediatr Gastroenterol Nutr; 1993 Jul; 17(1):32-8. PubMed ID: 8102399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects.
    Ewe K; Eckardt V; Kanzler G
    Scand J Gastroenterol Suppl; 1988; 148():70-5. PubMed ID: 2906479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis.
    Kruis W; Judmaier G; Kayasseh L; Stolte M; Theuer D; Scheurlen C; Hentschel E; Kratochvil P
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):391-6. PubMed ID: 7614099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [5-aminosalicylic acid treatment of ulcerative colitis during the acute phase in patients resistant or intolerant to salazopyrine].
    Cappello M; Puleo A; Calabrese A; Cipolla C; Orlando A; Gatto G; Oliva L; Cottone M
    Recenti Prog Med; 1987 Feb; 78(2):76-8. PubMed ID: 2884701
    [No Abstract]   [Full Text] [Related]  

  • 12. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
    Nakajima H; Munakata A; Yoshida Y
    J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of chronic inflammatory intestinal diseases with 5-aminosalicylic acid].
    Malchow H
    Internist (Berl); 1987 Jan; 28(1):14-20. PubMed ID: 2883152
    [No Abstract]   [Full Text] [Related]  

  • 14. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial.
    Meyers S; Sachar DB; Present DH; Janowitz HD
    Gastroenterology; 1987 Dec; 93(6):1255-62. PubMed ID: 2890550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Salozosulphapyridine and its metabolites in ulcerative colitis and Crohn disease].
    Rubinstein BE
    Ugeskr Laeger; 1982 Feb; 144(5):304-6. PubMed ID: 6122297
    [No Abstract]   [Full Text] [Related]  

  • 16. Controlled trial comparing olsalazine and sulphasalazine for maintenance treatment of ulcerative colitis.
    Jewell DP; Ireland A
    Scand J Gastroenterol Suppl; 1988; 148():45-7. PubMed ID: 2906477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
    Feurle GE; Helmstädter V
    Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
    [No Abstract]   [Full Text] [Related]  

  • 18. Olsalazine in patients intolerant of sulphasalazine.
    Ireland A; Jewell DP
    Scand J Gastroenterol; 1987 Nov; 22(9):1038-40. PubMed ID: 2892247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulfasalazine and new analogues.
    Friedman G
    Am J Gastroenterol; 1986 Feb; 81(2):141-4. PubMed ID: 2868653
    [No Abstract]   [Full Text] [Related]  

  • 20. Will there be a next generation of sulfasalazine?
    Goldman P
    Gastroenterology; 1982 Nov; 83(5):1138-41. PubMed ID: 6126420
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.